NCT06643299

Probiotic Use for Recovery Enhancement From Long COVID-19

PURE-LC - Probiotic Use for Recovery Enhancement From Long COVID

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 180 (estimated)
• Sponsor: Rush University Medical Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to learn if probiotics can improve symptoms and quality of life in participants with Long COVID.

Detailed description

The goal of this clinical trial is to learn if probiotics can improve symptoms and quality of life in participants with Long COVID. The main questions it aims to answer are: 1. Do probiotics reduce the number and severity of symptoms in those with Long COVID? 2. Do probiotics improve the physical and mental health quality of life in those with Long COVID? 3. Do probiotics improve return to work and daily activities in those with Long COVID? Researchers will compare probiotics to a placebo (a look-alike substance that contains no probiotics) to see if probiotics work to treat Long COVID. Participants will take the study medication (placebo or probiotic) for 4 months. They will then cross over (take the other medication) for an additional 4 months. Participants will complete a survey at baseline, 4 months, and 8 months.

Conditions

• Post-Acute COVID-19 Syndrome

Interventions

Type	Name	Description
DRUG	Probiotic Agent	BlueBiology: Ultimate Care probiotic pill taken once daily for a four-month period.
OTHER	Placebo	Placebo produced to be identical in taste and appearance to the probiotic agent, taken once daily for a four-month period.

Timeline

• Start date: 2025-05-13
• Primary completion: 2026-05-01
• Completion: 2026-07-01
• First posted: 2024-10-16
• Last updated: 2025-09-03

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study